Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.65 |
| ▸ | AHR | P35869 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MGAM | O43451 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8290481 | 0.88 | MAPT (0.76) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL1562661 | 0.88 | CYP1A2 (0.76) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL6635372 | 0.88 | CYP1A2 (0.76) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL1562660 | 0.88 | CYP1A2 (0.76) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL8292509 | 0.87 | GAA (0.71) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL8291227 | 0.87 | TDP1 (0.85) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL21258283 | 0.87 | CYP1A2 (0.71) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL8292186 | 0.87 | CYP1A2 (0.71) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL8292485 | 0.86 | TDP1 (0.71) | CYP1A2GAATDP1MAPTPOLB | |
| SCHEMBL6055366 | 0.84 | CYP1A2 (1.00) | CYP1A2GAATDP1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| US-20130131340-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | FORMAN BARRY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037257-A2 | NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131340-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | ESRRA, ESRRB, ESR2 | CYP1A2 358/4885GAA 4062/4885TDP1 4660/4885 |
| US-20070037752-A1 | Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases | DNPEP, PREP, ANPEP | CYP1A2 1126/4885GAA 227/4885TDP1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.